Therapeutic potential for protein kinase C inhibitor in vascular restenosis

Richard Qinxue Ding, Jerry Tsao, Hong Chai, Daria Mochly-Rosen, Wei Zhou

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Vascular restenosis, an overreaction of biological response to injury, is initialized by thrombosis and inflammation. This response is characterized by increased smooth muscle cell migration and proliferation. Available pharmacological treatments include anticoagulants, antiplatelet agents, immunosuppressants, and antiproliferation agents. Protein kinase C (PKC), a large family of serine/threonine kinases, has been shown to participate in various pathological stages of restenosis. Consequently, PKC inhibitors are expected to exert a wide range of pharmacological activities therapeutically beneficial for restenosis. In this review, the roles of PKC isozymes in platelets, leukocytes, endothelial cells, and smooth muscle cells are discussed, with emphasis given to smooth muscle cells. We will describe cellular and animal studies assessing prevention of restenosis with PKC inhibitors, particularly targeting -α, -β -δ, and ζ isozymes. The delivery strategy, efficacy, and safety of such PKC regulators will also be discussed.

Original languageEnglish (US)
Pages (from-to)160-167
Number of pages8
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume16
Issue number2
DOIs
StatePublished - Jun 2011
Externally publishedYes

Keywords

  • Migration
  • Proliferation
  • Protein kinase C
  • Smooth muscle cell
  • Vascular restenosis

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this